The MHCII immune activation assay is prognostic for disease free survival in basal-like TNBC breast cancer patients in the GEICAM/9906 clinical trialMiguel Martin, Katherine L. Updike,Alvaro Rodriguez-Lescure,Lourdes Calvo,Jesus Herranz,Nuria Martin,Philip S. Bernard,Katherine E. VarleyCANCER RESEARCH(2020)引用 0|浏览21暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要